CD8A and neoplasm: To determine if a reduction in tumor burden and prolonged survival accompanied enhancement of anti-tumor CD8+ T cell responses, tumor size and animal morbidity were monitored in both TMEV Xho1-OVA8 and TMEV-wt treated mice.